MA-NUMARES
Leading NMR diagnostics company numares AG today announced that the company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AXINON® IVD System , a NMR-platform for AI-driven, metabolomics-based diagnostics. If cleared, AXINON® would become the first NMR-based clinical laboratory system using AI-evaluated metabolic data. Several multi-marker assays for AXINON® will cover numerous unmet medical needs, in order to prevent, diagnose and treat disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005057/en/
The clearance of AXINON® would bring a novel diagnostic approach to clinical laboratories, the combination of several metabolic biomarkers, so-called metabolite constellations, analyzed by advanced nuclear magnetic resonance (NMR) technology and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software.
"This U.S. regulatory filing for its diagnostics platform is an important milestone for numares ," said Winton Gibbons, President - US and co-Chief Executive Officer of numares . “After entering into collaborations on joint diagnostics development with analytical instrumentation and solution provider Bruker Corporation in January 2021, and with Mayo Clinic Laboratories in 2019, this FDA submission is the first step in our common endeavor to bring NMR diagnostics into routine clinical use, and make metabolomics-based diagnostics accessible to the patients.”
numares is currently developing multi-marker algorithms for several diagnostic tests on the AXINON® IVD System . These include AXINON® GFRNMR to reliably assess kidney function by improved determination of glomerular filtration rate (GFR). numares expects to submit this test to the FDA also in the first half 2021. The third assay AXINON® renalTX-SCORE® is intended to reliably identify early kidney rejection in post-transplant surveillance, and be submitted to the FDA in 2022. Further multi-marker tests are in development, e.g., for liver disease, cancer detection, and multiple sclerosis.
Dr. Maulik Shah, numares’ Medical Director comments: “AXINON® provides clinical laboratories with a powerful technology that leverages the information-rich metabolome with artificial intelligence to give healthcare professionals new insights into disease diagnosis and management for improved patient outcomes. At the same time, automation capabilities, excellent precision, easy operability will allow easy adaption of the FDA-cleared system by clinical laboratories and will make AXINON® an indispensable routine diagnostic tool in precision medicine.”
“The 510(k) submission of our AXINON® System is an important step and prerequisite to further strengthen commercialization of numares’ products in the United States”, concludes Dr. Volker Pfahlert, co-CEO of numares and chairman of the executive board. “Metabolic disorders are a rapidly increasing problem and major challenge to today’s healthcare systems. Patients will benefit from our approach to consider the patient's metabolome with sophisticated algorithms. Once cleared by the FDA, we believe AXINON® has the potential to meaningfully improve health outcomes and quality of life for millions of patients.”
The AXINON® System consists of AI-based AXINON® Software , ready-to-use AXINON® kits, and an advanced NMR technology, refined by numares’ proprietary Magnetic Group SignalingTM to ensure highly standardized and automated processing of serum or urine samples in high-throughput.
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005057/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Emerges as a Global Hub for Medical Innovation and Collaborative R&D18.11.2025 13:55:00 CET | Press release
In the United Arab Emirates, where cities like Abu Dhabi and Dubai consistently rank among the world's most forward-thinking, the Emirate of Sharjah, the country's cultural and knowledge capital, has decisively positioned itself as a premier hub for research and innovations in healthcare. This transformation is primarily driven by the Sharjah Research, Technology and Innovation Park (SPARK) formerly SRTIP, SRTI Park. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118121763/en/ SPARK Headquarters (SPARK HQ) (Photo: AETOSWire) This ambition was powerfully demonstrated during the recent "Sharjah Next: Healthcare" forum, which transcended a typical conference, evolving into a powerful statement of intent. It assembled a host of global healthcare luminaries, including Professor Sir Magdi Yacoub, a pioneer in cardiothoracic surgery; Professor Humaid Obaid Al-Shamsi, a leading Emirati oncologist; and Dr. Vladimir Ivkovic of Harv
Options Selects atNorth Data Center for Private AI Solution18.11.2025 13:14:00 CET | Press release
Options Technology (Options), the leading provider of capital markets infrastructure, today announced a partnership with atNorth, the leading Nordic high-density colocation and built-to-suit datacenter provider, to host its expanded private AI solution, at atNorth’s ICE02 data center in Iceland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118956675/en/ Options Selects atNorth Data Center for Private AI Solution Options infrastructure expansion results from increasing demand from financial firms, such as hedge funds, investment banks, and proprietary trading firms, for high-density computing power, driven by the rapid adoption of AI for trading strategies, risk management, and data analytics. The business aims to address a gap in the market for private cloud infrastructure specifically tailored to the requirements of the financial services industry. Recognizing the need for a secure, sustainable, AI ready and cost-effec
Loyalty Upgraded: Hilton Honors Introduces Faster Path to Elite Status and Reveals New Premium Tier – Diamond Reserve18.11.2025 13:02:00 CET | Press release
Benefits include best-in-industry room upgrades, guaranteed late check-out and exclusive member support Evolution of the award-winning Hilton Honors loyalty program makes earning status even more achievable and more rewarding. New Diamond Reserve tier represents exclusive level of recognition and benefits within Hilton Honors. Diamond status more quickly attainable, and Gold status now the most valuable mid-tier status. Hilton Honors members will continue to enjoy the benefits they value and appreciate the most. Committed to rewarding loyalty at every stage of the travel journey, today Hilton (NYSE: HLT) announced exciting changes to its award-winning Hilton Honors loyalty program. Debuting this January, Hilton will introduce its most elite tier yet – Diamond Reserve – with new elevated benefits, including a Confirmable Upgrade Reward that can be instantly redeemed at the time of booking, guaranteed 4 p.m. late checkout, and exclusive customer service support. This press release featur
NIQ Launches New Brand Traction Score Designed to Reveal How Effectively FMCG Brands Convert Shelf Presence Into Real Consumer Purchases18.11.2025 12:45:00 CET | Press release
Coca-Cola, Philadelphia and Nutella rank highest among the top 15 FMCG brands that have the highest traction score in Western EuropeThe higher the score, the more effectively a brand not only reaches consumers but also converts visibility into salesNIQ also highlights a growing trend across Europe, where rising brand traction scores are closely aligned with the strongest sales growth Coca-Cola has been recognised as the top FMCG brand in Western Europe for its success in driving conversions, according to NielsenIQ (NIQ)’s Brand Traction Score, a new metric that measures how effectively brands convert their shelf presence into actual consumer purchases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118769598/en/ NIQ Brand Traction Score The NIQ Brand Traction Score combines two of NIQ’s most powerful data sources: insights from its Consumer Panel, which tracks how frequently shoppers buy a brand, and its Retail Measuremen
Barilla Opens Its New Innovation Center to Drive Food Innovation Worldwide18.11.2025 12:37:00 CET | Press release
A reimagined space where research, technology, and collaboration merge with global expertise to advance the future of Barilla’s pasta, sauces, and bakery products How can we bring the excellence of Italian culinary tradition into the future? How can we transform everyday products into experiences that surprise the senses, create emotions, and accompany people in moments of pleasure, sharing, and discovery? The answer for Barilla Group is the Barilla Innovation & Technology Experience (BITE) in Parma, marking the company’s most significant investment in food innovation in recent years. With almost 14,000m², more than €20 million invested and an additional €2 million per year dedicated to equipment upgrades, BITE stands as a global hub designed to foster development across the Group’s portfolio. Pasta, sauces, and bakery become a territory of exploration here, where research and technology serve Barilla's passion for good food. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom